US2005256053A1PendingUtilityA1

Combined use of a GLP-1 compound and another drug for treating dyslipidemia

50
Individually held — no corporate assignee on recordPriority: Dec 29, 2001Filed: Jul 20, 2005Published: Nov 17, 2005
Est. expiryDec 29, 2021(expired)· nominal 20-yr term from priority
Inventors:Lotte Bjerre KnudsenJohan Selmer
A61P 43/00A61P 3/06A61K 31/366A61K 31/785A61P 3/00A61K 31/225A61K 45/06A61K 31/401A61K 38/26
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Claims

exact text as granted — not AI-modified
1 . A method for treating dyslipidemia in a patient in need thereof, said method comprising administration to said patient of an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of an antidyslipidemic drug.  
   
   
       2 . The method according to  claim 1 , wherein the GLP-1 compound is a stable derivative of a GLP-1 analog.  
   
   
       3 . The method according to  claim 1 , wherein the GLP-1 compound is Arg 34 , Lys 26 (N ε -(γ-Glu(N α -hexadecanoyl)))-GLP-1(7-37).  
   
   
       4 . The method according to  claim 1 , wherein the GLP-1 compound is exendin-4 or an analog or derivative thereof.  
   
   
       5 . The method according to  claim 1 , wherein said antidyslipidemic drug is a statin.  
   
   
       6 . The method according to  claim 1 , wherein said antidyslipidemic drug is selected from the group consisting of atorvastatin, lovastatin, fluvastatin, simvastatin, pravastatin, rivastatin, itavastatin and ZD-4522.  
   
   
       7 . The method according to  claim 1 , wherein said antidyslipidemic drug is a squalene synthase inhibitor.  
   
   
       8 . The method according to  claim 7 , wherein said squalene synthase inhibitor is selected from the group consisting of YM-53601 and ER-27856.  
   
   
       9 . The method according to  claim 1 , wherein said antidyslipidemic drug is a bile acid binding resin.  
   
   
       10 . The method according to  claim 9 , wherein said bile acid binding resin is selected from the group consisting of cholestyramine and cholestipol.  
   
   
       11 . The method according to  claim 1 , wherein said antidyslipidemic drug is an interscapular brown adipose tissue (IBAT) inhibitor.  
   
   
       12 . The method according to  claim 11 , wherein said IBAT inhibitor is S-8921.  
   
   
       13 . A method according to  claim 1 , wherein said GLP-1 compound is administered in a regimen which additionally comprises administration of said antidyslipidemic drug.  
   
   
       14 . A method according to  claim 1 , wherein said GLP-1 compound and said antidyslipidemic drug are co-administered.  
   
   
       15 . A method according to  claim 1 , wherein said GLP-1 compound is a parenteral medicament.  
   
   
       16 . A method according to  claim 1 , wherein said antidyslipidemic drug is an oral medicament.  
   
   
       17 . A method according to  claim 1 , wherein said GLP-1 compound and said antidyslipidemic drug are administrered in suboptimal dosages.  
   
   
       18 . A method according to  claim 1 , wherein the effective amount of said GLP-1 compound is a dosage of from 0.5 μg/kg/day to 10 μg/kg/day.  
   
   
       19 . A method according to  claim 1 , wherein the effective amount of said GLP-1 compound is a dosage of from 0.1 μg/kg/day to 1 μg/kg/day.  
   
   
       20 . A method according to  claim 1 , wherein the effective amount of said antidyslipidemic drug is a dosage of from 0.01 mg/day to 10 mg/day.  
   
   
       21 . A method according to  claim 1 , wherein the effective amount of said antidyslipidemic drug is a dosage of from 0.1 mg/day to 3 mg/day.  
   
   
       22 . A method according to  claim 1 , wherein the effective amount of said antidyslipidemic drug is a dosage of less than 2 mg/day.

Join the waitlist — get patent alerts

Track US2005256053A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.